News

The European Lead Factory (ELF) and Société de Chimie Thérapeutique (SCT) are pleased to host a webinar for the French scientific community in which the opportunities and benefits of collaborating with the ELF will be explained.

High Content and Phenotypic Screening are two cell-based approaches offered by the European Lead Factory (ELF). They are performed on cells or tissues grown in vitro and often combine substantial automation, big data handling, and customised analysis workflows running on high performance computing systems.

Phenotypic screening is a powerful approach to identifying novel chemical starting points for drug discovery. It uses cell-based assays and advanced data analytics to develop quantitative fingerprints that can uncover new drug targets and pathways underpinning disease-related biology.

How to optimise your assay for High Throughput Screening (HTS) at the European Lead Factory (ELF). This was the topic of the latest ELF webinar, which took place on Thursday 28 January.

In a new article, published in Frontiers in Immunology, researchers from the

Dr James Duffy is a Director of Drug Discovery at the Medicines for Malaria Venture (MMV), a not-for-profit product development partnership (PDP) working to reduce the burden of malaria by discovering, developing and delivering new, effective and affordable antimalarial drugs.

The focus of the second European Lead Factory (ELF) webinar, which took place on Thursday 10 December, was on small and medium-sized enterprises (SMEs) and how ELF can help SMEs achieve their drug discovery ambitions.

The European Lead Factory (ELF) offers a pharmacological strategy to aid in the discovery of new candidate molecules against SARS-CoV-2 causing COVID-19.

Have you identified a disease mechanism that should be explored in a drug discovery project? Then you may have also considered developing a screening assay to find new chemical starting points that could serve as candidates for drug development.

Registration is now open for the second in a series of webinars hosted by the European Lead Factory (ELF).

On Thursday 12 November, the European Lead Factory (ELF) hosted the first in a series of webinars. With these webinars, the ELF team aims to engage and maintain contact with the broader scientific community, now that live conferences and in-person meetings are not possible.

Phenotypic screening is a powerful approach to identifying novel chemical starting points for drug discovery, offering the potential to uncover new drug targets and pathways underpinning disease-related biology. High Content Screening (HCS) is one of the phenotypic screening approaches offered by the European Lead Factory (ELF).

COVID-19 has led to in-person events being suspended or cancelled. In an effort to keep the European Lead Factory (ELF) community connected and informed of ongoing activities, we are pleased to announce that we will be organising a series of webinars on different programmes and topics within the ELF portfolio.

Saturday, 10 October is World Mental Health Awareness Day. As a project involved in advancing drug candidates to address mental health disorders and other diseases, the European Lead Factory (ELF) supports World Mental Health Awareness Day. At the ELF, there are several initiatives running that could ultimately contribute to better treatments of mental health conditions

In a paper recently published in the SLAS Discovery Journal of Biomolecular Screening, European Lead Factory (ELF) scientists from the Pivot Park Screening Centre (PPSC), shared their experiences working on the assay development and ultra-High Throughput Screening (u-HTS) of crowed-sourced drug targets during the first phase of E